Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells via viral delivery

US11845932B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11845932-B2
Application numberUS-202217829263-A
CountryUS
Kind codeB2
Filing dateMay 31, 2022
Priority dateApr 24, 2020
Publication dateDec 19, 2023
Grant dateDec 19, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Nucleic acid-guided nuclease editing in mammalian cells may include passaging mammalian cells, in an automated closed cell editing instrument, into smaller aggregates when the aggregates exceed 50-300 microns in size. A library of viral particles may be delivered to the mammalian cells at a multiplicity of infection such that each mammalian cell receives one or no viral particle. The library may include viral vectors with an editing cassette including a pair of gRNA coding sequence and donor DNA. Conditions may be provided to allow a viral vector of the viral vectors to integrate into the mammalian cells. Enriching for mammalian cells may be done with an integrated viral vector. A nucleic acid-guided nuclease or nuclease fusion or a coding sequence for a nucleic acid-guided nuclease or nuclease fusion may be delivered to the enriched mammalian cells and conditions may be provided to allow editing in the mammalian cells.

First claim

Opening claim text (preview).

We claim: 1. A method of performing nucleic acid-guided nuclease editing in mammalian cells in an automated closed editing instrument comprising the steps of: passaging mammalian cells, in an automated closed cell editing instrument comprising a growth module and a liquid handling system, into smaller aggregates when the aggregates exceed 50-300 microns in size; delivering a library of viral particles to the mammalian cells in the growth module at a multiplicity of infection (MOI) such that each mammalian cell receives one viral particle or no viral particle, wherein the library of viral particles comprises viral vectors each comprising an editing cassette comprising a pair of gRNA coding sequence and donor DNA; providing conditions to allow a viral vector of the viral vectors to integrate into cellular chromatin or persist in cell nucleuses of the mammalian cells as an extrachromosomal episome; enriching for mammalian cells with an integrated viral vector; delivering a nucleic acid-guided nuclease or nuclease fusion or a coding sequence for a nucleic acid-guided nuclease or nuclease fusion to the enriched mammalian cells; and providing conditions to allow editing to take place in the mammalian cells. 2. The method of claim 1 , wherein the growth module is a bioreactor. 3. The method of claim 1 , wherein the automated closed cell editing instrument comprises a reagent cartridge. 4. The method of claim 1 , wherein the liquid handing system comprises a manifold with one or more connections to the bioreactor. 5. The method of claim 1 , wherein the liquid handling system comprises reagent receptacles individually connected to the growth module. 6. The method of claim 1 , wherein the mammalian cells are induced pluripotent stem cells. 7. The method of claim 1 , wherein the mammalian cells are primary cells. 8. The method of claim 1 , wherein the growth module is a bioreactor with at least one impeller and the mammalian cell aggregates are passaged into smaller aggregates by increasing revolutions per minute of at least one impeller. 9. The method of claim 8 , wherein the growth module is a bioreactor with at least two impellers and the mammalian cell aggregates are passaged into smaller aggregates by increasing revolutions per minute of the at least two impellers. 10. The method of claim 1 , wherein the viral vector is a lentiviral vector. 11. The method of claim 1 , wherein the viral vector is an adeno-associated virus vector. 12. The method of claim 1 , wherein the viral vector is an adenovirus vector. 13. The method of claim 1 , wherein the viral vector is an oncoretrovirus vector. 14. The method of claim 1 , wherein the viral vector is a herpesvirus vector. 15. The method of claim 1 , wherein the viral vector is delivered to the cells on microcarriers at an MOI of approximately 0.05 to 1.0. 16. The method of claim 15 , wherein the viral vector is delivered to the cells on microcarriers at an MOI of approximately 0.1 to 0.5. 17. The method of claim 16 , wherein the viral vector is delivered to the cells on microcarriers at an MOI of approximately 0.1 to 0.3. 18. The method of claim 1 , wherein the aggregates of mammalian cells are passaged into small aggregates of mammalian cells via at least one driving impeller in a bioreactor. 19. The method of claim 1 , wherein the growth module is a bioreactor with a lid assembly. 20. The method of claim 19 , wherein the lid assembly comprises at least one sensor port. 21. The method of claim 20 , wherein the at least one sensor port in the lid assembly is configured to accommodate a sensor to monitor capacitance of the cells and medium in a tapered main body of the growth vessel; a sensor to measure O 2 concentration of transduced and/or transfected cells and medium in the tapered main body of the growth vessel; a sensor to measure CO 2 of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel; a sensor to measure pH of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel; a sensor to measure lactate concentration of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel; a sensor to measure glucose concentration of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel; a sensor to measure biomass of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel; or a sensor to measure optical density of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel. 22. The method of claim 20 , wherein there are at least two sensor ports in the lid assembly each configured to accommodate a sensor to monitor capacitance of transduced and/or transfected cells and medium in a tapered main body of the growth vessel; a sensor to measure O 2 concentration of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel; a sensor to measure CO 2 of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel; a sensor to measure pH of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel; a sensor to measure lactate concentration of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel; a sensor to measure glucose concentration of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel; a sensor to measure biomass of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel; or a sensor to measure optical density of the transduced and/or transfected cells and medium in the tapered main body of the growth vessel. 23. The method of claim 20 , wherein the lid assembly further comprises a temperature probe. 24. The method of claim 20 , wherein the lid assembly further comprises a camera port.

Assignees

Inventors

Classifications

  • Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors · CPC title

  • specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads or physically stretching molecules · CPC title

  • Heating or cooling apparatus (autoclaves B01J3/04); Heat insulating devices · CPC title

  • Well or multiwell plates (C12M25/04 takes precedence) · CPC title

  • Microfluidic devices; Capillary tubes (integrated microfluidic structures B01L3/5027; microreactors B01J19/0093) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11845932B2 cover?
Nucleic acid-guided nuclease editing in mammalian cells may include passaging mammalian cells, in an automated closed cell editing instrument, into smaller aggregates when the aggregates exceed 50-300 microns in size. A library of viral particles may be delivered to the mammalian cells at a multiplicity of infection such that each mammalian cell receives one or no viral particle. The library ma…
Who is the assignee on this patent?
Inscripta Inc
What technology area does this patent fall under?
Primary CPC classification C12N15/1082. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).